 SAN DIEGO, Feb. 17, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation Nasdaq: ADMP Company today announced that it recently received a notice that one of its patent applications relating to its ZIMHITM high dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office. The allowed claims describe a naloxone composition at a dose greater than or equal to five milligrams configured for administration as an injection. The company believes this patent should protect and strengthen the existing intellectual property associated with the product candidate. 